Collaborating with clinical focus
This article was originally published in Scrip
Executive Summary
For some time now pharmaceutical industry chiefs have struggled with rising research costs, longer development times, falling R&D productivity and increasing pressures on operating margins. For the past decade, we have seen pharma companies reorganise their R&D structures, reduce their dependency on in-house R&D, smooth out chinks in the clinical supply chain and even focus on more targeted approaches to try and iron out the inefficiencies of drug research. With not much too show for their endeavours.